DexCom, Inc. (DXCM) Financial Statements
DexCom, Inc. (DXCM) reported trailing twelve-month revenue of $5.0B (up 15.5% year on year) and net income of $999.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $1.4B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DXCMDexCom, Inc.Follow DXCM — free
—
Price chart with a free account
- Market cap
- 29.4B
- P/E TTM
- 30.9
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Feb, in 109 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.08 | 0.10 | 0.16 | 0.26 | 0.40 | 0.57 | 0.72 | 1.03 | 1.48 | 1.93 | 2.45 | 2.91 | 3.62 | 4.03 | 4.66 | 4.97 | |
| Gross profit | 0.04 | 0.05 | 0.10 | 0.18 | 0.28 | 0.38 | 0.49 | 0.66 | 0.93 | 1.28 | 1.68 | 1.88 | 2.29 | 2.44 | 2.80 | 3.10 | |
| Research & development | 0.03 | 0.04 | 0.04 | 0.07 | 0.14 | 0.16 | 0.19 | 0.20 | 0.27 | 0.36 | 0.52 | 0.48 | 0.51 | 0.55 | 0.60 | 0.60 | |
| Operating income | -0.04 | -0.06 | -0.03 | -0.02 | -0.06 | -0.06 | -0.04 | -0.19 | 0.14 | 0.30 | 0.27 | 0.39 | 0.60 | 0.60 | 0.91 | 1.14 | |
| Pre-tax income | -0.04 | -0.06 | -0.03 | -0.02 | -0.06 | -0.06 | -0.05 | -0.13 | 0.10 | 0.30 | 0.26 | 0.39 | 0.71 | 0.71 | 1.09 | 1.28 | |
| Income tax | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.25 | 0.04 | 0.05 | 0.17 | 0.13 | 0.25 | 0.28 | |
| Net income | -0.04 | -0.05 | -0.03 | -0.02 | -0.06 | -0.07 | -0.05 | -0.13 | 0.10 | 0.55 | 0.22 | 0.34 | 0.54 | 0.58 | 0.84 | 1.00 | |
| Diluted EPS ($) | -0.68 | -0.79 | -0.42 | -0.30 | -0.72 | -0.78 | -0.58 | -1.44 | 1.10 | 1.33 | 0.53 | 0.82 | 1.30 | 1.42 | 2.09 | 2.52 | |
| Diluted shares (bn) | — | — | — | — | — | — | — | — | 0.092 | 0.420 | 0.429 | 0.427 | 0.425 | 0.413 | 0.406 | — |
USD billions · SEC XBRL
DexCom, Inc. — questions
- What is DexCom, Inc.'s revenue?
- $5.0B over the twelve months to 2026-06-30, up 15.5% year on year, from its 10-Q and 10-K filings.
- What is DexCom, Inc.'s net income?
- $999.7M over the twelve months to 2026-06-30.
- What is DexCom, Inc.'s free cash flow?
- $1.4B over the twelve months to 2026-06-30.
- What are DexCom, Inc.'s diluted earnings per share?
- $2.52 over the twelve months to 2026-06-30.
Every figure on this page comes from DexCom, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.